Dynavax Technologies Past Earnings Performance
Past criteria checks 2/6
Dynavax Technologies has been growing earnings at an average annual rate of 47.6%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 28.4% per year. Dynavax Technologies's return on equity is 3%, and it has net margins of 7.9%.
Key information
47.6%
Earnings growth rate
54.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 28.4% |
| Return on equity | 3.0% |
| Net Margin | 7.9% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Dynavax Technologies: What The Stock Buyback Means, What It Doesn't
Nov 13Dynavax Technologies Corporation (NASDAQ:DVAX) Surges 31% Yet Its Low P/S Is No Reason For Excitement
Nov 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?
Oct 12Dynavax Technologies: Slow And Steady Wins The Race
Sep 05Dynavax Technologies: A Two Trick Pony Operating With A Single Trick
Aug 23Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings
Aug 14Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?
Jul 12Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S
May 22Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain
May 10Dynavax: Holding Firm Despite Its Missing Cash Cow
Mar 23Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Mar 06Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry
Jan 31These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely
Aug 02Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet
Jun 02We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease
May 03Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly
Jan 16Clover, Dynavax COVID-19 vaccine gets EU GMP certificate
Sep 20Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?
Sep 12The Alphavaxers: Dynavax And Novavax, 2 Quarters On
Aug 22Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats
Aug 04Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?
Jun 03Dynavax: Evolving Endemic Situation Adds To Its Risk
May 23Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest
May 12Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt
May 10Dynavax Technologies: Full Speed Ahead
Mar 01Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly
Jan 28Revenue & Expenses Breakdown
How Dynavax Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 261 | 20 | 168 | 0 |
| 30 Jun 24 | 250 | 17 | 163 | 0 |
| 31 Mar 24 | 236 | 9 | 159 | 0 |
| 31 Dec 23 | 232 | -6 | 160 | 0 |
| 30 Sep 23 | 361 | 61 | 151 | 0 |
| 30 Jun 23 | 459 | 111 | 143 | 0 |
| 31 Mar 23 | 656 | 236 | 143 | 0 |
| 31 Dec 22 | 723 | 293 | 126 | 0 |
| 30 Sep 22 | 733 | 320 | 124 | 0 |
| 30 Jun 22 | 674 | 228 | 119 | 0 |
| 31 Mar 22 | 470 | 104 | 104 | 0 |
| 31 Dec 21 | 439 | 72 | 92 | 0 |
| 30 Sep 21 | 258 | -39 | 81 | 0 |
| 30 Jun 21 | 163 | -6 | 76 | 0 |
| 31 Mar 21 | 113 | -62 | 73 | 0 |
| 31 Dec 20 | 40 | -75 | 72 | 0 |
| 30 Sep 20 | 38 | -97 | 74 | 0 |
| 30 Jun 20 | 35 | -138 | 72 | 0 |
| 31 Mar 20 | 40 | -129 | 73 | 0 |
| 31 Dec 19 | 35 | -156 | 72 | 0 |
| 30 Sep 19 | 30 | -159 | 70 | 0 |
| 30 Jun 19 | 21 | -163 | 68 | 0 |
| 31 Mar 19 | 14 | -160 | 64 | 0 |
| 31 Dec 18 | 8 | -159 | 65 | 0 |
| 30 Sep 18 | 3 | -146 | 58 | 0 |
| 30 Jun 18 | 1 | -128 | 48 | 0 |
| 31 Mar 18 | 0 | -109 | 40 | 0 |
| 31 Dec 17 | 0 | -95 | 27 | 0 |
| 30 Sep 17 | 8 | -89 | 26 | 0 |
| 30 Jun 17 | 8 | -102 | 32 | 0 |
| 31 Mar 17 | 10 | -111 | 36 | 0 |
| 31 Dec 16 | 11 | -112 | 37 | 0 |
| 30 Sep 16 | 4 | -118 | 36 | 0 |
| 30 Jun 16 | 5 | -113 | 30 | 0 |
| 31 Mar 16 | 4 | -108 | 25 | 0 |
| 31 Dec 15 | 4 | -107 | 22 | 0 |
| 30 Sep 15 | 6 | -102 | 21 | 0 |
| 30 Jun 15 | 7 | -102 | 19 | 0 |
| 31 Mar 15 | 8 | -103 | 18 | 0 |
| 31 Dec 14 | 11 | -91 | 18 | 0 |
| 30 Sep 14 | 12 | -90 | 24 | 0 |
| 30 Jun 14 | 12 | -76 | 24 | 0 |
| 31 Mar 14 | 13 | -68 | 22 | 0 |
| 31 Dec 13 | 11 | -75 | 27 | 0 |
Quality Earnings: DVAX has high quality earnings.
Growing Profit Margin: DVAX's current net profit margins (7.9%) are lower than last year (16.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DVAX has become profitable over the past 5 years, growing earnings by 47.6% per year.
Accelerating Growth: DVAX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DVAX had negative earnings growth (-66.5%) over the past year, making it difficult to compare to the Biotechs industry average (16.6%).
Return on Equity
High ROE: DVAX's Return on Equity (3%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dynavax Technologies Corporation is covered by 15 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Elemer Piros | Cantor Fitzgerald & Co. |
| Joshua Schimmer | Evercore ISI |
| Jonathan Miller | Evercore ISI |